NCT00400517View on ClinicalTrials.gov

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

sargramostim

administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day

DRUG

thalidomide

doses up to 400 mg/day

PROCEDURE

conventional surgery

SOC care surgery

PROCEDURE

neoadjuvant therapy

post radical prostatectomy

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00400517 - GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter